| Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial C Faivre-Finn, M Snee, L Ashcroft, W Appel, F Barlesi, A Bhatnagar, ... The Lancet Oncology 18 (8), 1116-1125, 2017 | 502 | 2017 |
| Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer H Usadel, J Brabender, KD Danenberg, C Jerónimo, S Harden, J Engles, ... Cancer research 62 (2), 371-375, 2002 | 421 | 2002 |
| Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients SV Harden, Y Tokumaru, WH Westra, S Goodman, SA Ahrendt, SC Yang, ... Clinical Cancer Research 9 (4), 1370-1375, 2003 | 232 | 2003 |
| Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma SV Harden, Z Guo, JI Epstein, D Sidransky The Journal of urology 169 (3), 1138-1142, 2003 | 179 | 2003 |
| Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies SV Harden, H Sanderson, SN Goodman, AAW Partin, PC Walsh, ... Journal of the National Cancer Institute 95 (21), 1634-1637, 2003 | 167 | 2003 |
| Intraoperative molecular margin analysis in head and neck cancer D Goldenberg, S Harden, BG Masayesva, P Ha, N Benoit, WH Westra, ... Archives of otolaryngology–head & neck surgery 130 (1), 39-44, 2004 | 147 | 2004 |
| Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer D Gale, K Heider, A Ruiz-Valdepenas, S Hackinger, M Perry, G Marsico, ... Annals of oncology 33 (5), 500-510, 2022 | 143 | 2022 |
| Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma Y Tokumaru, SV Harden, DI Sun, K Yamashita, JI Epstein, D Sidransky Clinical cancer research 10 (16), 5518-5522, 2004 | 109 | 2004 |
| Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR) MJ Seckl, CH Ottensmeier, M Cullen, P Schmid, Y Ngai, D Muthukumar, ... Journal of Clinical Oncology 35 (14), 1506, 2017 | 105 | 2017 |
| Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury GJ Doherty, AM Duckworth, SE Davies, GF Mells, R Brais, SV Harden, ... ESMO open 2 (4), e000268, 2017 | 104 | 2017 |
| Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres OS Din, SV Harden, E Hudson, N Mohammed, LS Pemberton, JF Lester, ... Radiotherapy and Oncology 109 (1), 8-12, 2013 | 86 | 2013 |
| British thoracic society guideline for pleural disease ME Roberts, NM Rahman, NA Maskell, AC Bibby, KG Blyth, JP Corcoran, ... Thorax 78 (Suppl 3), s1-s42, 2023 | 85 | 2023 |
| Biallelic inactivation of the RIZ1 gene in human gastric cancer Y Tokumaru, S Nomoto, C Jeronimo, R Henrique, S Harden, B Trink, ... Oncogene 22 (44), 6954-6958, 2003 | 84 | 2003 |
| Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy … J Conibear, B Chia, Y Ngai, AT Bates, N Counsell, R Patel, D Eaton, ... BMJ open 8 (4), e020690, 2018 | 61 | 2018 |
| IDEAL-CRT: a phase 1/2 trial of isotoxic dose-escalated radiation therapy and concurrent chemotherapy in patients with stage II/III non-small cell lung cancer DB Landau, L Hughes, A Baker, AT Bates, MC Bayne, N Counsell, ... International Journal of Radiation Oncology* Biology* Physics 95 (5), 1367-1377, 2016 | 59 | 2016 |
| Quantitative assessment of inter-clinician variability of target volume delineation for medulloblastoma: quality assurance for the SIOP PNET 4 trial protocol CE Coles, ACF Hoole, SV Harden, NG Burnet, N Twyman, RE Taylor, ... Radiotherapy and Oncology 69 (2), 189-194, 2003 | 58 | 2003 |
| Stage III non-small cell lung cancer management in England JB Adizie, A Khakwani, P Beckett, N Navani, D West, I Woolhouse, ... Clinical Oncology 31 (10), 688-696, 2019 | 56 | 2019 |
| Image-guided radiotherapy to manage respiratory motion: lung and liver J Dhont, SV Harden, LYS Chee, K Aitken, GG Hanna, J Bertholet Clinical oncology 32 (12), 792-804, 2020 | 48 | 2020 |
| Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer BG Masasyesva, BC Tong, MV Brock, T Pilkington, D Goldenberg, ... International journal of cancer 113 (6), 1022-1025, 2005 | 47 | 2005 |
| Mouse mammary tumor‐like env gene as a molecular marker for breast cancer? R Zangen, S Harden, D Cohen, P Parrella, D Sidransky International journal of cancer 102 (3), 304-307, 2002 | 46 | 2002 |
